Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population - Liu - 2022 - Journal of Diabetes Investigation - Wiley Online Library
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Summary of the effects of iDegLira and iGlarLixi on postprandial... | Download Scientific Diagram
Frontiers | Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
Mixed reaction to Novo Nordisk obesity trial - PMLiVE
In a showdown with Sanofi, FDA questions Novo's PhIII data for IDegLira | Fierce Biotech
REMIT-iDegLira - Research Studies - PHRI - Population Health Research Institute of Canada
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
The clinical benefits of IDegLira in DUAL VII were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy - Media Centre | EASD
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V - Media Centre | EASD
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Novo Nordisk invests $60 million in expansion of Kalundborg site
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Peter Falck Christens, Manager Biostatistics IdegLira, (Novo Nordisk) — Ministry of Music
Switching to a fixed-ratio combination of insulin degludec/liraglutide ( IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the
Insulin Degludec Insulin Aspart (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Dosificación, Titulación y Aplicación de iDegLira - Novo Nordisk
Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared With Insulin Glargine U100 Plus Insulin Aspart in the U.S. - Endocrine Practice
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Novel insulin/GLP-1 combo succeeds in phase III trial | MDedge Endocrinology
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
